They might have outstanding earnings, this quarter's results are not out yet. I follow the trading of Quidels' stock very closely. I like what I see in the trading. Don't understand why the large short position still exists though. Another point or two rise will result in losses for the shorts.
Then it's off to the races, no resistance above where we are today.
I also don't understand why the earnings forecasts have not been updated significantly.
If you search "Google" and "influenza" and then click US trends, you will see that it looks worse in the US than the pandemic did. By far the worst and earliest flu season for over eight years.
Between the strong sales of flu tests this season, and the potential increase in revenue expected for the new portfolio of tests recently approved in the US and EU, as well as additional tests expected for approval in 2013, Quidel has a lot of growth potential. No wonder Zacks has it rated as a "Buy". Over time, Quidel may become a takeover target of a larger diagnostics company (e.g. the diagnostic division of Abbott, or BD, or JNJ) that wants to acquire the platforms of the newer molecular diagnostic tests Quidel is in the process of launching (e.g. Sofia, Wildcat, DHI's cell based tests, and the new nanotech HIV quatitative disposable test being developed with Northwestern University which is currently undergoing clinical trials on infants in Africa. The next year of two will be rewarding for the patient investor in Quidel.